(Q51189191)

1 April 2018

title

Advances from clinical trials in juvenile idiopathic arthritis. (English)

1 reference

1 April 2018

juvenile rheumatoid arthritis

main subject

1 reference

Daniel J Lovell

1

1 reference

1 April 2018

Nicola Ruperto

series ordinal

2

1 reference

1 April 2018

Edward H Giannini

series ordinal

3

1 reference

1 April 2018

Alberto Martini

series ordinal

4

1 reference

1 April 2018

language of work or name

English

0 references

publication date

9 July 2013

1 reference

1 April 2018

Nature Reviews Rheumatology

published in

1 reference

1 April 2018

volume

9

1 reference

1 April 2018

issue

9

1 reference

1 April 2018

page(s)

557-563

1 reference

1 April 2018

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.105

exact match

0 references

cites work

Juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Auranofin, methotrexate, but no placebo: comment on the article by Williams et al

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Preliminary definition of improvement in juvenile arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Use of unlabelled and off licence drugs in children. Use of unlicensed drugs may be recommended in guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

The German etanercept registry for treatment of juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A new era in the treatment of systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

The safety profile of biologic therapies for juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Rates of malignancy associated with juvenile idiopathic arthritis and its treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Pediatric rheumatology: JIA, treatment and possible risk of malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Report on malignancies in the German juvenile idiopathic arthritis registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

Malignancies in juvenile idiopathic arthritis: a preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.105

A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule

31 March 2020

1 reference

12 December 2020

Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design

1 reference

12 December 2020

Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children

1 reference

12 December 2020

Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis

1 reference

12 December 2020

International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001

1 reference

12 December 2020

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis

1 reference

12 December 2020

Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data.

1 reference

12 December 2020

Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

12 December 2020

Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?

1 reference

12 December 2020

Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis

1 reference

12 December 2020

Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.105

1 reference

1 April 2018

1 reference

1 April 2018